Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cetirizine reduces the number of tryptase-positive mast cells in psoriaticpatients: A double-blind controlled study
Autore:
Pestelli, E; Caproni, M; Giomi, B; Volpi, W; Spallanzani, A; Cardinal, C; Floriani, J; Fabbri, P;
Indirizzi:
Univ Florence, Clin Dermatol 2, Dept Dermatol Sci, I-50122 Florence, ItalyUniv Florence Florence Italy I-50122 rmatol Sci, I-50122 Florence, Italy Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy Mario Negri Inst Pharmacol Res Milan Italy I-20157 I-20157 Milan, Italy
Titolo Testata:
INTERNATIONAL JOURNAL OF TISSUE REACTIONS-EXPERIMENTAL AND CLINICAL ASPECTS
fascicolo: 3, volume: 23, anno: 2001,
pagine: 97 - 103
SICI:
0250-0868(2001)23:3<97:CRTNOT>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSPECTIVE CLINICAL-TRIAL; HISTAMINE-RELEASE; CATHEPSIN-G; HUMAN-LUNG; IN-VITRO; SKIN; RANITIDINE; CHYMASE; IMMUNOTHERAPY; LOCALIZATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Caproni, M Univ Florence, Clin Dermatol 2, Dept Dermatol Sci, Via Pergola 58, I-50122Florence, Italy Univ Florence Via Pergola 58 Florence Italy I-50122 nce, Italy
Citazione:
E. Pestelli et al., "Cetirizine reduces the number of tryptase-positive mast cells in psoriaticpatients: A double-blind controlled study", INT J TISS, 23(3), 2001, pp. 97-103

Abstract

Psoriatic plaque contains an increased number of mast cells that are thought to play an important role in the initiation and maintenance of the disease through the release of mediators such as histamine, proteoglycans, proteinases and cytokines. To verify the possible participation of these cells in the chronic inflammatory cutaneous response in psoriasis, we performed a double-blind controlled study to investigate the presence and activation oftryptase-positive mast cells in the lesional skin of 19 patients affected by active psoriasis vulgaris minima compared with five healthy age-matched subjects. Psoriatic patients were randomized into two groups (A and B). Thefirst group was treated with cetirizine (10 mg/three times a day for 15 days) and the second one was treated with placebo, Both groups underwent clinical staging [psoriasis area and severity index (PASI) score] and immunohistochemical evaluation [alkaline phosphatase antialkaline phosphatase (APAAP) procedure] before and after treatment, In group A, the PASI score ranged from 3.8 (SE +/- 1.00) to 1.8 (SE +/- 0.68) and in group B, from 5.0 (SE +/- 0.98) to 3.4 (SE +/- 0.47). The mean number of tryptase-positive mast cells for field, mainly distributed in the perivascular and periadnexal sites,ranged from 40.8 (SE +/- 7.15) to 21.6 (SE +/- 3.04) in group A and from 25.1 (SE +/- 3.78) to 26.3 (SE +/- 3.59) in group B (ANOVA test f = 6.95; gl= 1.16; p = 0.02). In our psoriatic patients, cetirizine significantly reduced the expression of tryptase-positive mast cells and produced a clinicalimprovement in erythema, suggesting a multilevel immunopharmacologic modulation of this antihistamine in psoriasis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 20:35:32